PharmaMar, a world-leading biopharmaceutical company, has announced the opening of a new affiliate in Austria with the aim of reinforcing the presence of the company within Europe, one of the world's leading oncology markets.

As Luis Mora, managing director at PharmaMar´s Oncology Business Unit, explains "The opening of this affiliate is part of our growth strategy in certain European countries; this allows us to offer a better attention to our customers through our own teams. From Austria we can operate directly in Eastern European countries such as Poland and the Czech Republic."

With this new affiliate in Austria, PharmaMar now has a presence, with its own structure, in eight European countries. The other subsidiaries are located in Italy, Germany, France, Switzerland, Spain, the United Kingdom and Belgium consolidating the company's business and distribution model.

According to GLOBOCAN data, in 2012 41,100 new cases of cancer were detected in Austria. It is estimated that the risk of suffering cancer before the age of 75 is 30% in men and 22% in women. Prostrate, breast and colorectal cancer are the most frequent types of tumor in Austria.